Form 4: Foghorn Therapeutics CEO Adrian Gottschalk Transfers Shares to Living Trust
SEC Form 4
CEO Adrian Gottschalk transferred 197,906 shares of Foghorn Therapeutics Inc. common stock from a Grantor Retained Annuity Trust to a Living Trust on April 9, 2025.
Summary
- On April 9, 2025, Adrian Gottschalk, CEO of Foghorn Therapeutics Inc., transferred 197,906 shares of the company's common stock from the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust (Gottschalk 2023 GRAT) to the Adrian H. Gottschalk Living Trust.
- Gottschalk serves as the trustee and sole current beneficiary of both trusts.
- Following the transaction, the Gottschalk Living Trust holds 464,207 shares, and the Gottschalk 2023 GRAT holds 47,497 shares.
- The total number of shares beneficially owned by Gottschalk remains at 511,704.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding a stock transfer. It doesn't convey any positive or negative sentiment about the company's performance or prospects.
Industry Context
This is a routine disclosure related to executive stock ownership and does not necessarily reflect a change in the company's financial health or strategic direction.
Stakeholder Impact
- The stock transfer has no immediate impact on shareholders, employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| May 26, 2023 | Date of the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust |
| September 8, 2009 | Date of the Adrian H. Gottschalk Living Trust |
| April 9, 2025 | Date of the stock transfer |
| April 10, 2025 | Date of the Form 4 filing |
Keywords
Foghorn Therapeutics, Adrian Gottschalk, stock transfer, beneficial ownership, Form 4, FHTX, trusts
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.